Clinical Trial Results:
Phase II study of oral PRednisone 5 mg bid plus EVerolimus in patients with metastatic renal cell cancer after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (PREV study)
Summary
|
|
EudraCT number |
2015-002419-14 |
Trial protocol |
IT |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
23 Apr 2025
|
First version publication date |
23 Apr 2025
|
Other versions |
|
Summary report(s) |
189.04_Final Report_17.09.18 The Oncologist-2017-Lolli |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.